Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05011422 | Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies | recruiting | Phase 1 | 50 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05082519 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL(IDEAL2) | recruiting | Phase 2 | 240 | Etan OrgelOTHER | 1 | Aug 19, 2026 |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05977673 | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy(FIL_Tisle-HL) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06399640 | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | recruiting | Phase 1 | 60 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06781359 | Study on Plasmablastic Lymphoma Patients(FIL_PlaLy) | recruiting | — | 200 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07070219 | A Study of CTD402 in T-ALL/LBL Patients(TENACITY-01) | recruiting | Phase 1 / Phase 2 | 118 | Imviva BioINDUSTRY | 2 | Aug 19, 2026 | clinicaltrials |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | recruiting | Phase 2 / Phase 3 | 215 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | recruiting | Phase 2 | 50 | Eden BiltiboOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07772024 | Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma(DOMMINO-2) | recruiting | Phase 3 | 450 | CellCentric Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774390 | Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL(I+V-LT) | recruiting | — | 323 | European Research Initiative on CLLNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774572 | Exploration of Circular RNA in B-cell Hematologic Malignancies | recruiting | Phase 1 | 30 | Ruijin HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03719105 | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | recruiting | Early Phase 1 | 40 | New York Medical CollegeOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05651932 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | recruiting | Phase 1 | 165 | K36 Therapeutics, Inc.INDUSTRY | 4 | Aug 18, 2026 | clinicaltrials |
| NCT06353191 | Biomarkers to Predict Cancer Therapy-related Cardiotoxicity | recruiting | — | 693 | Mayo ClinicOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06376526 | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma(IMMUNOPLANT) | recruiting | Phase 2 | 150 | Dickran Kazandjian, MDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06656494 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | recruiting | Phase 1 | 266 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 3 | Aug 18, 2026 | clinicaltrials |
| NCT07012109 | Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) | recruiting | Phase 1 | 90 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia(PROSPERA) | recruiting | Phase 2 | 66 | TheradexINDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies | recruiting | Phase 1 | 48 | Sawa Ito, MDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)(Soursop) | recruiting | Early Phase 1 | 20 | Roger StrairOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04515810 | Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning | recruiting | N/A | 400 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT05463796 | InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05850234 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)(DURGA-1) | recruiting | Phase 1 / Phase 2 | 232 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06184321 | Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | recruiting | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06218602 | Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06528301 | A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | recruiting | Phase 1 | 106 | Umoja BiopharmaINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06927466 | A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. | recruiting | Phase 1 | 33 | Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07105059 | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07227584 | ALL Backbone in AYAs | recruiting | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07285239 | Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma(PrE1005) | recruiting | Phase 3 | 500 | PrECOG, LLC.OTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | recruiting | Phase 1 | 50 | Stanford UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | recruiting | Phase 1 | 90 | Andrew Hantel, MDOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07673367 | Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04776941 | Expressive Writing for the Management of Stress in Cancer Survivors | recruiting | N/A | 414 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05091372 | Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 94 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06274788 | Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | recruiting | — | 40 | Fresenius KabiINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06296368 | DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics(DISCOVERY) | recruiting | N/A | 500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06459024 | Master Framework For Relapse or Refractory Acute Myeloid Leukemia(IMPACT STREAM) | recruiting | — | 4,000 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 6 | Aug 14, 2026 | clinicaltrials |
| NCT06713837 | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.(IMPACT-AML) | recruiting | Phase 3 | 339 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 7 | Aug 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2026source: clinicaltrials